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 Abstract	  
IMPROVING PROGNOSTIC MODELS IN BREAST CANCER WITH BIOSTATISTICAL 
ANALYSIS OF THE PI3-KINASE PATHWAY.  
Elliot James Rapp, Jena P. Giltnane, David L. Rimm, Annette Molinaro.  
Department of Biostatistics, Yale School of Public Health, Yale University 
School of Medicine, New Haven, CT. 
Our hypothesis was that prognostic models for breast cancer that 
incorporate both clinical variables and biomarkers in the PI3 Kinase molecular 
pathway will improve upon the clinical models of TNM staging and the 
Nottingham Prognostic Index (NPI). Our specific aim was to develop models 
that misclassify fewer patients than TNM and NPI with the outcome of dead of 
disease at ten years. Our population cohort was the YTMA49 cohort, a series of 
688 samples of invasive ductal breast carcinoma collected between 1961 and 
1983 by the Yale University Department of Pathology. Tissue MicroArray (TMA) 
analysis was performed and biomarker expression level was determined using 
Automated Quantitative Analysis (AQUA) technology for thirteen biomarkers in 
the PI3 Kinase pathway, including an overall expression level and expression 
levels by subcellular compartment.  Eleven clinical variables were also 
assembled from our cohort.  Exhaustively searching the multivariate space, we 
used logistic regression to predict our outcome of dead of disease at ten years.  
Validation was performed using Leave One Out Cross Validation (LOOCV).  
Misclassification estimates provided the means to compare different models, 
with lower misclassification estimates indicating superior models.  Confidence 
 intervals were constructed using bootstrapping with one thousand iterations.  
We developed a helper computer program named Combination Magic to enable 
us to develop sophisticated models that included both interactions between 
variables and transformations of variables (e.g. logarithm).   
Overall our best univariate models were NPI (misclassification estimate 
(ME): 0.326, confidence interval (CI): 0.292 to 0.359), Nodal status (ME: 0.353, 
CI: 0.322 to 0.493), and TNM (ME: 0.367, CI: 0.313 to 0.447). Our best 
univariate models from the PI3 Kinase biomarkers were FOX01_NU (ME: 0.369, 
CI: 0.336 to 0.415), AKT1_TM (ME: 0.373, CI: 0.335 to 0.412), and PI3Kp110_TM 
(ME: 0.377, CI: 0.343 to 0.431).  Our best bivariate models were 
pTumor*PathER (ME: 0.328, CI: 0.308 to 0.443), pNode + NuGrade (ME: 0.333, 
CI: 0.305 to 0.434), and AKT1_NN + Fox01_NU (ME: 0.338, CI: 0.307 to 0.391).  
Our best trivariate models were pTumor + mTOR_NN + PI3Kp110_TM + 
pTumor*PI3Kp110_TM (ME: 0.296, CI: 0.273 to 0.375), pTumor + AKT1_NU + 
Fox01_NU + pTumor*AKT1_NU (ME: 0.298, CI: 0.275 to 0.38), and pTumor + 
mTOR_TM + PI3Kp110_TM + pTumor*PI3Kp110_TM (ME: 0.299, CI: 0.276 to 
0.378).  Our best multi-variate model was Fox01_NU + AKT1_NU + mTOR_MB + 
p70S6K_NU + AVG_BCL2_TM + Fox01_NU*AKT1_NU*mTOR_MB (ME: 0.295, CI: 
0.274 to 0.393).  None of these models was statistically superior to the clinical 
models of TNM and NPI.
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Introduction	  
Although many advances have been made in breast cancer treatment 
over the last few decades, it remains a deadly disease with significant 
financial, health, and emotional costs for breast cancer patients and survivors.  
Of particular concern for both doctors and patients is likelihood of recurrence 
after resection of the primary tumor.  This likelihood can have an immediate 
impact on choice of treatment, including the type of medical treatment and 
the type of surgical resection, from lumpectomy to simple mastectomy to 
radical mastectomy. 
The likelihood of recurrence also carries an emotional toll long after 
treatment of the primary tumor is completed.  Many patients live in fear of 
recurrence.  Patients may choose a more aggressive chemotherapy treatment 
than necessary, which carries its own health risks and litany of side effects.  
Patients with a particularly high risk profile may even opt for prophylactic 
mastectomy of a healthy breast. 
Clinical models have been developed to assess the risk of metastasis in 
breast cancer and are widely used in clinical practice, despite the fact that 
their utility continues to be a matter of debate.  The best known are TNM 
staging and the Nottingham Prognostic Index (NPI).  Each has been validated in 
numerous clinical trials.   
TNM staging is based on tumor size, number of positive lymph nodes, and 
the presence of metastasis.  The TNM classification of breast cancer was 
updated in 2002 and again in 2009.  As our work was performed prior to the 
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2009 definition, the 2002 definition was used for this analysis.  Although widely 
used historically, TNM staging of breast cancer has been criticized as having 
limited utility in actual clinical practice.  As far back as 1992 Barr and Baum 
called for its removal from clinical decision making, arguing that it ignores 
many factors relevant to both surgical treatment and prognosis, and that 
factors it does include are difficult to reliably assess clinically, with 
unacceptably high false positive and negative rates (1).   
More recently, Benson continues the criticism of the clinical utility of 
TNM staging in breast cancer (2).  He notes that TNM staging was developed at 
a time when the pathological model of cancer metastasis was thought to 
happen in an orderly, Halstedian fashion, with cancer spreading in a logical 
manner from its site of origin to local lymph nodes to distant sites of 
metastasis.  However, small tumors with aggressive hematogenous spread do 
not follow this model, and tend to be more aggressive than larger tumors with 
lymphatic spread.  Thus, TNM staging is particularly unhelpful for this type of 
tumor, motivating the need for a more helpful alternative.  
The NPI prognostic model is based on tumor size, number of positive 
lymph nodes, and the histologic grade.  It yields a continuous number that falls 
into one of six prognostic groups, from Excellent Prognostic Group (EPG) to 
Very poor Prognostic Group (VPG).  NPI is the only breast cancer staging model 
with prospective validation both intra and inter-center (3).  It differs from TNM 
in that it includes histologic grade, yet like TNM it does not incorporate 
biomarkers. Thus, neither TNM staging nor the Nottingham Prognostic Index 
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incorporate the growing body of knowledge regarding the significance of 
different subtypes of breast cancer and the importance of metabolic and 
signaling pathways in breast cancer growth and metastasis. 
With advances in our understanding of the molecular pathways involved 
in breast cancer, there has been renewed interest in developing prognostic 
models that include biomarkers to overcome limitations of TNM staging and the 
Nottingham Prognostic Index and more accurately predict metastasis and/or 
recurrence in breast cancer.  Significantly, laboratory tools such as Automated 
Quantitative Analysis (HistoRX, New Haven, Connecticut) also allow us to more 
accurately quantify expression levels of biomarkers in various pathways 
significant in cancer, improving the accuracy and reproducibility of models 
using biomarkers.   
More accurate prognostic models will provide value to both physicians 
and patients.  Biomarker analysis can also provide important information about 
the likely efficacy of various drugs that are targeted at different molecular 
pathways active in breast cancer.  A notable example is the use of the 
pharmaceutical Trastuzumab to target the HER2/neu receptor, which has been 
widely used in clinical practice since its FDA approval in 1998 (4). 
After mutations of the p53 tumor suppressor gene, mutations within the 
Phosphatidyl Inositol-3 Kinase (PI3 Kinase or PI3K) pathway are the most 
common mutations leading to human cancer (5).  Recent work has shown the 
particular significance of PI3 Kinase mutations in human breast cancer (6).  
Given the need for more accurate prognostic models in breast cancer, the 
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likelihood that inclusion of biomarkers in prognostic models can improve upon 
the existing clinical models, and the importance of the PI3K pathway in breast 
cancer, we chose to evaluate whether a search of the covariate space of 
various messengers in the PI3 Kinase pathway and clinical variables can offer 
improved prognostic models when compared to the clinical gold standards of 
TNM and NPI.  
Specific	  Aims	  of	  Thesis	  
Aim	  1	  
Determine whether an exhaustive search of the covariate space of the 
PI3 Kinase molecular pathway and clinical variables in metastatic breast cancer  
can improve prognostic models over the existing clinical standards of TNM 
staging and the Nottingham Prognostic Index (NPI) with the outcome of dead of 
disease at ten years. Evaluate whether interactions between different 
biomarkers in the PI3 Kinase pathway and logarithmic values can improve upon 
the prognostic models previously identified. 
Aim2	  
Develop a reliable methodology to create and evaluate prognostic 
models with an arbitrary number of interactions, sub-interactions, and custom 
terms.  In addition, structure our computational analysis to allow us to both 
exhaustively search the model space and selectively create models by hand.  
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Methods	  
Statistical	  Platform	  
All computations were performed using The R Project for Statistical 
Computing, an open-source statistical language and environment freely 
available on the Internet (7).   
Tumor	  Cohort	  
The YTMA49 cohort has been previously described (8).  Briefly, it 
consists of 688 samples of invasive ductal breast carcinoma collected between 
1961 and 1983 from the Yale University Department of Pathology archives.  The 
mean and median age of diagnosis were 58.1 and 58.0, respectively.  The mean 
and median follow-up times were 12.8 and 8.9 years, respectively.  The cohort 
contains approximately half node-positive and half node-negative specimens. 
Data	  Acquisition	  
Data acquisition was performed by Jena Giltnane, at the time a MD/PhD 
candidate at Yale University School of Medicine.  She analyzed 539 metastatic 
breast cancer biopsy cores from the YTMA49 cohort using Automated 
Quantitative Analysis (described below).  In addition to quantifying expression 
levels of thirteen biomarkers in the PI3 Kinase pathway (see Table One), she 
assembled eleven clinical variables (see Table Two).  Together, these 24 
variables were included as the covariates for model building.  However, as 
noted below, each biomarker was further characterized by its expression level 
in three subcellular compartments.  Thus, there were a total of 63 possible 
inputs to our model generation (52 biomarkers and 11 clinical variables). 
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AQUA	  Analysis	  of	  the	  PI3	  Kinase	  Pathway	  
Automated Quantitative Analysis (HistoRX, New Haven, Connecticut), 
known as AQUA, has been previously described (9).  Traditional scoring of 
protein expression performed by pathologists using immunohistochemistry and 
visual inspection of tumor slides is limited by inter-operator variability and lack 
of reproducibility.  AQUA technology assigns a value from 0 to 255 to represent 
the level of biomarker expression, with a higher number indicating greater 
expression.  Its increased granularity of expression levels and high 
reproducibility when compared to traditional methods is designed to allow for 
more accurate prognostic models. 
When performing AQUA quantification, the technician distinguishes areas 
of tumor from stromal elements by staining with antikeratin and creating an 
epithelial tumor mask.  After the operator visual sets an intensity threshold to 
distinguish between cancerous and non-cancerous areas, the AQUA software 
defines each area as “on” (tumor) or “off” (non-tumor).  By convention, TM 
(“Tumor Mask”) describes the overall expression level in cancerous cells.   
In addition, AQUA allows quantification of protein expression by 
subcellular compartmentalization.  NU (“Nuclear”) describes the expression 
level in the nuclear compartment.  MB (“Membrane”) describes the expression 
level in the cellular membrane.  NN (“Non-Nuclear”) describes the expression 
level in the non-nuclear, non-membranous portion of the cell.  The ability to 
localize biomarkers in the PI3 Kinase pathway by subcellular compartment is 
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designed to allow for improved prognostic models by more precisely describing 
the metabolic activity of the pathway. 
Model	  Search	  
One of the challenges of our analysis was model selection.  One 
possibility is to use artificial intelligence algorithms to search the model space 
and use pruning techniques to eliminate unfavorable portions of the covariate 
space.  This is potentially advantageous given limited computing resources.  
However, without deep understanding of the domain space, it is difficult to 
accurately predict which portions of the covariate space are unfavorable for 
analysis.  Another possibility is to use classic Classification and Regression 
Trees (CART) (10) to determine good variables on which to split and then 
construct models by hand.  Although this lessens the dependence of model 
quality on the researcher’s domain expertise, it remains prone to error.   The 
most foolproof method, given sufficient computing resources, is to exhaustively 
search the variable space.  With the availability of two high-performance 
clusters (described below) on which to perform our analysis, we chose the 
exhaustive search option.   
With exhaustive search of the covariate space, it becomes imperative to 
accurately create all possible combinations of variables for models of varying 
complexity (e.g., univariate, bivariate, trivariate, and so forth).  Given 
combinatorial explosion, this can be a time-consuming task.  In addition, we 
desired the ability to create specialized runs with models that included 
straightforward interactions of the form “Y ~ A*B*C”, where Y is the outcome 
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and A, B, and C are inputs, sub-interactions of the form “Y ~ A + B+ C + A*B”, 
where “A*B” defines an interaction between A and B in addition to their 
independent effects, and custom and/or transformed terms (e.g., logarithmic 
terms, such as Y ~ A + log(B/C)). 
Logistic	  Regression	  Analysis	  and	  Misclassification	  
Given that our goal was to improve prognostic models of breast cancer, 
we chose dead or alive of disease as our outcome.  An important consideration 
was the appropriate time interval.  Shorter time intervals would classify 
patients with later recurrence as having “survived” breast cancer.  Longer time 
intervals would compromise the analysis by introducing the confounding nature 
of comorbidities that are common in older patients, as well as increasing the 
number of patients that did not have sufficient follow up.  A ten year time 
interval was chosen as a compromise.  Thus, our outcome was death due to 
breast cancer within ten years of the initial diagnosis. 
As we needed a statistical methodology that would predict this binary 
outcome, we chose logistic regression.  The logistic regression computation was 
performed using R’s glm (“generalized linear model”) function.   
Leave	  One	  Out	  Cross	  Validation	  
In order to estimate prediction error of our models, we chose Leave One 
Out Cross Validation (LOOCV).  In this methodology, each patient is left out of 
the training set in turn and used in the test set.  A logistic regression analysis is 
performed on the training set.  Maintaining the parameters of the resulting 
model, if it correctly predicts the outcome (i.e., alive or dead at ten years) for 
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the patient left out (i.e., the single patient in the test set), then its 
classification is correct.  If it incorrectly predicts this outcome, then its 
classification is incorrect.  After all n-iterations of LOOCV, there are as many 
classifications as patients.  By dividing the incorrect classifications by the total 
number of classifications, we arrive at a misclassification estimate.  Our goal in 
this research project was to minimize the misclassification estimate, thereby 
improving our ability to accurately predict alive/dead status at ten years. 
Note that due to missing data values, not every patient will be included 
in the analysis when creating a misclassification estimate for a given model.  
Thus, as a measure of quality, we counted the number of successful predictions 
that were used to construct each misclassification estimate (the denominator 
of the misclassification estimate).  
In addition to misclassification, we computed Area Under the Curve 
(AUC) from ROC curves (Receiver Operator Curves).  The ROC curves were 
constructed using R’s rcorr.cens function from the Hmisc library (11). 
In order to format the data in a manner palatable to R, we were 
required to make a number of changes.  For example, R does not allow 
numerals at the start of column or row names in a data table.  Another 
potential issue was “factor” variables.  These include classification variables 
(e.g., TumorType could be Ductal or Lobular) and ordinal variables 
(pathologist-scored biomarker expression level scored as a 0, 1, 2 or 3).  In R, 
the former group is automatically recognized, whereas the latter group must 
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be explicitly designated as a factor; otherwise, it will be interpreted as a 
continuous variable.   
Another consideration was the alphabetical order of the factor names.  
This is due to the fact that R designates whichever factor is first alphabetically 
as the baseline.  In order to set the factor with the largest number of instances 
as baseline, we would programmatically recode the values when necessary, 
using 0, 1, 2 … n to represent the various categories in order of prevalence, 
and then explicitly designate each relevant variable as a factor to prevent its 
interpretation as a continuous variable. 
Bootstrapping	  and	  Confidence	  Intervals	  
Next, we needed to develop confidence intervals for our models, 
allowing us to compare two models and determine whether their 
misclassification estimates were statistically different. A common method for 
forming confidence intervals is via bootstrapping, which entails building 
training sets by sampling the data with replacement (12).  This did not change 
the total number of patients in the training set, but it did mean that patients 
could be included two or more times, whereas other patients would not be 
included at all.  By repeating this process 1000 times,  it was possible to 
construct a confidence interval by evaluating the 2.5 and 97.5 percentiles.  
Cluster	  Runs	  
Runs were performed on two different high-performance computing 
clusters maintained by the Yale University Life Sciences Computing Center, 
supported by NIH Grant RR19895.  The first, BulldogC, contains one hundred 
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and thirty compute nodes.  Each consists of dual 3.2 Ghz EM64T Xeon, 64-bit 
processors with eight GB of available RAM.  The second, BulldogI, contains one 
hundred and seventy compute nodes. Each consists of two dual core 3.0 GHz 
Xeon 5160 processors with sixteen GB of available RAM.  Runs varied greatly in 
complexity and required anywhere from a few hours to a week of processing 
time spread over one to one hundred and eighty processors. 
Given the enormous size and complexity of the runs, gracefully 
recovering from errors and having the ability to re-run selective inputs became 
a priority.  As noted earlier, we gained the ability to reproduce parts of the run 
by extracting model creation from the analysis code and passing discrete units 
of work into the R analysis function (represented by our input files).   
R was particularly sensitive to some data configurations.  This was 
especially true in the case of factor variables.  For example, in cases of a 
patient with a unique value for a factor variable, a R run-time error would 
occur when the patient was left out of model creation and then used for 
prediction during LOOCV.  Such a failure would cause the entire input file to 
fail and it was difficult to pinpoint the responsible formula.  To gracefully 
recover from these errors, we wrapped with R’s tryCatch function the code for 
generating the logistic regression model, making the prediction, and computing 
the Area Under the Curve (AUC).   
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Results	  
Univariate	  Results	  
Univariate Mis.Est. AUC n Mean 0.025 0.975 
NPI 0.326 0.644 473 0.326 0.292 0.359 
~pNodal Stage 0.353 0.597 539 0.372 0.322 0.493 
TNM 0.367 0.609  0.367 0.313 0.447 
~Metastasis 
Stage 0.368 0.537 536 0.367 0.334 0.398 
~Fox01_NU 0.369 0.524 434 0.375 0.336 0.415 
~AKT1_TM 0.373 0.5 415 0.374 0.335 0.412 
~PI3Kp110_TM 0.377 0.539 403 0.386 0.343 0.431 
~mTOR_TM 0.382 0.5 429 0.383 0.346 0.419 
~NFkB_TM 0.383 0.5 439 0.389 0.35 0.433 
~HER2_MB 0.385 0.524 535 0.391 0.357 0.425 
 
Figure	  1:	  Selected	  Univariate	  Results	  
Not surprisingly, the clinical models of NPI and TNM were superior to any 
single biomarker in the PI3 Kinase pathway.  This is likely because each of 
these clinical models incorporates multiple data points into a single marker of 
disease severity.  Interestingly, nodal status (the presence of metastasis in 
adjacent lymph nodes) was by itself slightly (but not significantly) more 
predictive than TNM overall, followed closely by whether or not the disease 
had metastasized distantly.  Of the PI3 Kinase variables, the nuclear 
localization of Fox01 and the overall expression of AKT1 were most predictive. 
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Bivariate	  Results	  
Bivariate Mis.Est. AUC n Mean 0.025 0.975 
pTumor * PathER 0.328 0.632 472 0.357 0.308 0.443 
pNode + NuGrade 0.333 0.645 502 0.357 0.305 0.434 
AKT1_NN + 
Fox01_NU 0.338 0.54 349 0.349 0.307 0.391 
 
Figure	  2:	  Selected	  Bivariate	  Results	  
Although our top three bivariate models all approached the univariate 
NPI model with misclassifications of 0.328, 0.333, and 0.338, respectively, 
none of them were quite able to match its 0.326 misclassification estimate.  
Furthermore, whereas the 95% confidence interval for misclassification by NPI 
was only 0.067 wide, the confidence intervals for two of our two top three 
bivariate models were considerably wider, indicating a greater likelihood that 
in future analysis our favorable results would not be replicated on independent 
data sets 
Trivariate	  Results	  
Trivariate 
Mis.Est. AUC n Mean 0.025 0.975 
pTumor + 
mTOR_NN + 
PI3Kp110_TM + 
pTumor*PI3Kp110
_TM 
0.296 0.648 311 0.322 0.273 0.375 
pTumor + 
AKT1_NU + 
Fox01_NU + 
pTumor*AKT1_N
U 
0.298 0.620 332 0.323 0.275 0.38 
19 
pTumor + 
mTOR_TM + 
PI3Kp110_TM + 
pTumor*PI3Kp110
_TM 
0.299 0.648 311 0.326 0.276 0.378 
 
Figure	  3:	  Selected	  Trivariate	  Results	  
With the additional information provided by a third variable, our top 
three trivariate results showed considerable improvement over our best 
bivariate results. They each had an improved misclassification estimate over 
NPI.  However, they also had a relatively wide 95% confidence interval of 
approximately 0.1.  Thus, the 95% confidence intervals of each overlapped with 
the 95% confidence intervals of the clinical models of TNM and NPI, and as a 
result none of the results were statistically significant. 
Multi-­‐Variate	  Results	  
 Mis. Est. AUC n Mean 0.025 0.975 
Fox01_NU + AKT1_NU + 
mTOR_MB + p70S6K_NU 
+ AVG_BCL2_TM + 
Fox01_NU*AKT1_NU*mT
OR_MB 
0.295 0.587 285 0.33 0.274 0.393 
Fox01_NU + AKT1_NU + 
mTOR_MB + 
AVG_BCL2_TM + 
p70S6K_NN + 
Fox01_NU*mTOR_MB*p7
0S6K_NN 
0.302 0.574 285 0.33 0.277 0.391 
Fox01_NU + AKT1_NU + 
mTOR_MB + AKT2_NN + 
AVG_BCL2_TM + 
p70S6K_NN + 
Fox01_NU*AKT1_NU*mT
OR_MB 
0.295 0.593 285 0.331 0.273 0.401 
Fox01_NU + AKT1_NU + 
mTOR_MB + cmyc_NU + 0.297 0.627 195 0.333 0.266 0.403 
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AVG_BCL2_TM + 
p70S6K_NN + 
AKT1_NU*p70S6K_NN 
 
Figure	  4:	  Selected	  Multivariate	  Results	  
Our top multivariate (i.e., greater than trivariate) results did not show 
improvement over our best trivariate models.  Misclassification estimates were 
similar but the confidence intervals widened.    
 
Discussion	  
Significance	  of	  Study	  Results	  
Our results were not significant when compared to the commonly used 
clinical models of TNM and NPI.  There are several possible reasons for this, 
including issues with missing data values, incomplete patient follow up in the 
YTMA49 cohort, choice of statistical methodology, and the significance of other 
biological pathways besides the PI3 Kinase pathway in breast cancer.   
First, there was a moderate amount of missing data, including clinical 
variables that were not available and AQUA variables that could not be 
computed due to inadequate tumor cores.  Logistic regression drops patients 
that do not have all values for all variables in the model, which leads to 
reduced accuracy of the model.   
Furthermore, patients with missing data values were also not available 
when creating our confidence intervals with bootstrapping.  With a smaller 
number of patients, this may have caused our confidence intervals to be wider 
than they would have been otherwise, and could have sacrificed statistical 
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significance in some cases.  Although it carries its own risks, imputing data may 
have improved our model accuracy and reduced our confidence intervals by 
making these patients available for regression analysis. 
Second, there was incomplete and inconsistent follow up of patients in 
the YTMA49 cohort.  This may have led to patients that were incorrectly 
classified as dead of disease that in actuality died of another cause.  It may 
also have led to patients that were incorrectly classified as dying of another 
cause.  In addition, some patients were lost to follow up altogether.   
Third, our results may also have suffered from our choice of outcome.  
The use of dead-of-disease at ten years arbitrarily separates a patient who has 
recurrence leading to death at nine years from one having the same outcome 
at ten years, even though these patients are effectively the same from a 
survival perspective.  Instead, choosing random forests with survival trees may 
have improved our results by eliminating the arbitrary cutoff of ten years (13, 
14).  Another option would be to use dead of disease at 15 years instead of 10 
years, given that the longer timeframe should eliminate the majority of late 
recurrences.  Separately, removing patients older than 80 would eliminate the 
confounding nature of the significant comorbidities in this elderly group of 
patients. 
Perhaps most significantly, since our study was designed, the importance 
of other pathways in breast cancer besides the PI3 Kinase pathway has become 
increasingly apparent.  This includes the p53 pathway and several others as 
well (15).  In some cases, multiple pathways may operate independently.  In 
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other cases, the pathways may have a dependency on each other.  For this 
reason, despite the tradeoff of a smaller cohort of patients, our analysis may 
have benefited from a focus only on the HER2-positive cases, as these are the 
cases for which the activity of the PI3-Kinase pathway has the most 
importance.   
Obviously, future studies of the potential of biomarker analysis to 
improve breast cancer prognosis would likely also benefit from the inclusion of 
other biological pathways that are significant in breast cancer. 
Statistical	  Methodology	  
Commonly, two statistical methodologies are used to create prognostic 
models to predict a binary outcome in human disease.  These are logistic 
regression and artificial neural network models (16). Other methodologies 
include k-Nearest Neighbors, Linear Discriminant Analysis, and Classification 
and Regression Trees (10). 
Significant advantages of logistic regression are that the methodology is 
well established and the coefficients of the models have intuitive clinical 
interpretations (17).  This allows us to compare the relative importance of 
various actors within the dysregulated PI3 Kinase pathway in breast cancer.  
Furthermore, logistic regression has been used in previous studies attempting 
to evaluate clinical models for breast cancer diagnosis (18, 19), and we were 
interested in comparing molecular models developed by this methodology to 
the clinical models used in practice.   
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Artificial neural networks are another viable option.  They have the 
advantage of not assuming a linear relationship between the model inputs and 
its outcome.  However, they are prone to over-fitting.  Additionally, their 
“black box” nature makes it impossible to reliably compare the relative 
importance of the various inputs in the model (17).  For the above reasons, we 
chose to use logistic regression over artificial neural networks in our analysis. 
However, in practice artificial neural networks have often performed 
well in elucidating previously unforeseen predictors in prognostic studies.  It 
would be instructive in a future study to compare the performance of artificial 
neural networks to the performance of logistic regression with regard to 
predicting survival in the YTMA49 cohort.   
Cross	  Validation	  
There are many methods of performing cross validation.  The three most 
commonly used are v-fold Cross Validation, Leave One Out Cross Validation, 
and Monte Carlo Cross Validation. 
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Figure	  5:	  v-­‐fold	  Cross	  Validation	  
In v-fold Cross Validation, the cohort is split into v equal partitions.  v-1 
of these partitions are used for the training set, while the vth partition is used 
for the test set.  In the next iteration, a different partition is used for the test 
set, while the remaining partitions are again used for the training set, and the 
process repeats.  Thus, each partition is used as the test set exactly once and 
is included in the training set v-1 times.  
Leave One Out Cross Validation (LOOCV) is the most extreme example of 
v-fold cross validation, where n is the size of the sample and v = n.  This means 
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that the regression analysis is performed n times, the size of the training set is 
n-1 patients, the size of the test set is one patient, and each patient is in the 
test set exactly once.  Its thoroughness results in a smaller bias than lesser 
forms of v-fold cross validation.  A tradeoff is that it is the most 
computationally intensive form of v-old cross validation.   
 
Figure	  6:	  Leave	  One	  Out	  Cross	  Validation	  
However, the fact that it is the most computationally intensive does not 
necessarily make it superior to cross validation with smaller values for v.  This 
is due to the fact that the n test sets are very similar to each other, resulting 
in a high variance.  The computational strain of LOOCV has made it less popular 
for large data sets, and as a result, its effectiveness in estimating 
generalization error has not been thoroughly studied (20). 
Monte Carlo Cross Validation is a third method of cross validation.  It 
introduces randomness by randomly splitting the cohort into a training set and 
a test set.  This process is repeated many times (e.g., 20, 50, or 1000 times).  
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It often employs similar splits to v-fold Cross Validation.  For example, with 
each iteration 90% of the observations may be in the training set and 10% in the 
test set.  As the number of iterations increases, this form of cross validation 
becomes increasingly computationally expensive. 
We chose to use (LOOCV) to estimate prediction error of our logistic 
regression models.  Despite its computational burden, LOOCV was chosen in 
part because we had sufficient computing power to perform it.  However, as 
noted by Molinaro (20), it has a high variance when compared to less extreme 
forms of v-fold cross validation.  Compared to n-fold or Monte Carlo cross 
validation, this may have created artificially large 95% confidence intervals, 
decreasing the likelihood that we would achieve statistical significance with 
our prognostic models when comparing them to the clinical gold standards of 
TNM and NPI. 
Model	  Creation	  with	  Combination	  Magic	  
All computations were performed using The R Project for Statistical 
Computing (RPS), an open-source language and environment.  In pre-study 
trials, the code for creating models was written in R alongside the R code for 
analyzing the logistic regression model and computing the misclassification.   
The limitation of this approach was several-fold.  First, while R is an 
excellent language for statistical analysis, data manipulation, and graphing, it 
lacks the advanced programming features found in more traditional 
programming languages.  Examples include the availability of classic data 
structures and strong debugging support.  As a result, it was difficult to create 
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a generalized algorithm for selecting all possible combinations of r from n, and 
such an algorithm would still not have the flexibility for custom model creation 
of the form we desired.  Second, by integrating model selection into a 
monolithic analysis run, we would not have the opportunity to selectively re-
run part of the analysis in case of failure.  Third, a graphical environment for 
manipulating parameters related to model selection would be significantly 
more user-friendly and offer improved ability to visualize the results of model 
construction in advance of our computing runs. 
We realized that by extracting the process of model creation from 
execution of the statistical runs, we could solve each of these issues.  A more 
conventional programming language would provide us with the libraries and GUI 
environment to create a flexible, generalized tool for model generation.  Given 
our familiarity with Java, this is the language we chose.  By generating our 
models in advance of the analysis run, and writing them out to multiple input 
files, the failure of any one file would allow the others to proceed, and the 
failed file could be re-run independently. 
We wrote a Java program (Combination Magic) to accomplish this task of 
model generation.  Combination Magic evolved to handle several additional 
features, which we will describe in the next paragraphs.   
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Figure	  7:	  Combination	  Magic	  
Most simply, Combination Magic takes a list of variables (of length n) and 
a “comparison level” (r) parameter that specifies how many variables should be 
in each combination.  For example, asking for all trivariate runs (taking r=3 
from n=84) yielded 95,284 combinations (i.e., models) for our data set.  (This is 
according to the formula for combinations of r objects from n choices, n!/[r! * 
(n-r)! )  The program’s output is two-fold.  The text box on the left contains all 
the possible combinations of the input variables.  In turn, this is the input to 
the model generator, which creates one or more models for each combination.  
These models are displayed in the textbox on the right.   
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Fundamentally, there are two types of models in Combination Magic, 
which we call “additive” (e.g., A + B + C) and “interactive” (e.g., A*B*C).  Note 
that interactive models, such as “A*B”, should be used when the variables A 
and B influence each other, with the expectation that the product of these two 
variables will meaningfully improve the predictive value of the model.     
Various parameters control the way that Combination Magic generates 
models from the combinations.  First, an “Include Smaller Levels” checkbox 
allows the user to include multiple levels in the output; for example, 
trivariate, bivariate, and univariate.  Second, the “Exclude Non-Interactions” 
checkbox allows you to remove pure additive models from the output.  Often 
you will want to run all additive models, and do all interactive models in a 
following run.  Third, Interaction Level specifies the level at which interactions 
are produced.  Note that this interaction level must be within the range of the 
Comparison Level (from 2 to Comparison Level if “Include Smaller Levels” is 
checked, otherwise just Comparison Level) to have any effect.  Fourth, the 
Sub-Interactions checkbox turns on generation of sub-interactions, while the 
adjacent Vars input designates the maximum number of terms in each sub-
interaction.  For example, when processing a quadvariate model, Vars = 3 
would yield sub-interaction terms that included both two variables and three 
variables, whereas Vars = 2 would just include the two-variable sub-
interactions. 
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Combination	  Magic	  Use	  Cases	  
 
Figure	  8:	  Combination	  Magic	  Use	  Case	  #1	  
This is a simple example of model creation.  There are five variables and 
the comparison level is one.  Since each variable is only compared to itself, this 
yields five possible models.  Note that we specified Z as the outcome variable.  
We also specified that the variable X should be included in every formula.  
Note that any variable included in this manner will not participate in 
comparisons, although this variable can be of any arbitrary form (e.g., an 
interaction such as X*Y or a logarithmic variable such as log X). 
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Figure	  9:	  Combination	  Magic	  Use	  Case	  #2	  
Now we have specified a comparison level of 3.  This creates models of 
the form “Z~A+B+C”.  Since we have checked “Include Smaller Levels”, we also 
have models of the form “Z~A+B” (i.e., a comparison level of 2).  In total, 25 
models are created. 
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Figure	  10:	  Combination	  Magic	  Use	  Case	  #3	  
Now, in addition to a comparison level of 3, we have specified an 
interaction level of 3.  This interaction level creates interactions of the form 
“A*B*C”.  Since we have selected the “Sub-Interactions” check box, models will 
also be created with smaller interactions up to the level specified.  In this 
case, this means the inclusion of interactions of 2 (e.g., A*B).  In total, 10 
combinations and 50 models are created. 
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Combinatorial	  Explosion	  and	  Java	  Heap	  Restrictions	  
We quickly realized that combinatorial explosion would not only slow 
down completion of our runs on the clusters, but also impact our ability to 
generate the models in Combination Magic due to heap and stack overflows.  In 
order to solve the stack overflow problem, the recursive combination algorithm 
was rewritten to avoid calling itself.  (It is only a pseudo-recursive function in 
that each call to the function only necessitates one “recursive” call until the 
base case is eventually reached, not two or more.)   
The heap overflow problem was more problematic.  Java has a heap size 
limit on various operating systems.  On Windows, it is 1.6 gigabytes.  Even after 
optimization and allocation of the maximum amount of memory, heap size 
would be exceeded whenever the number of models reached the low millions.  
To solve this, we added the ability to selectively generate ranges of output 
(e.g., combinations 500,000 to 999,999, and so forth).  We also added a small 
calculator, available in the “Calculate Combinations” tab, to calculate the 
number of combinations to expect from a set of parameters r and n.  This 
assisted in our planning of runs, allowing us to generate maximum model 
output without causing a heap overflow.  
Despite these optimizations and workarounds, we reached a limit beyond 
which we could not search exhaustively.  For our data, exhaustively searching 
the 5-variable space would require examining 30,872,016 models (5 from 84).  
Because LOOCV requires repeating the generation of each logistic regression 
model 539 times, alternating leaving out each patient, exhaustively searching 
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the 5-variable space would actually require more than 16 billion distinct and 
expensive logistic regression calculations, and that’s without interactions, sub-
interactions, or custom terms.  We did not have enough computer power to 
accomplish this task.  Thus, we needed a new strategy. 
For runs beyond quadvariate, instead of selecting from all 100 variables 
(recall that each PI3-Kinase biomarker has several subcellular compartmental 
expression levels), we split the variables into two "families".  One family 
consisted of the best subcellular compartmentalizations of the PI3K 
biomarkers.  The second family consisted of the AQUA and pathologist-scored 
ErbB family markers and ER/PR, along with the clinical variables pTumor, 
pMet, and pNode. We will refer to these as the PI3K and ErbB families, 
respectively.  5- and 6-variable runs were performed on each family. 
Next, we merged the results from each family into an aggregate run that 
included the best models from each family.  Combination Magic was extended 
with new functionality to enable the merge.  We will use the example of 
creating a six-variable "merged" run from the best thirty models of the two 5-
variable runs of each family.  The merge consisted of selecting six variables 
from the pool of variables created by all pair-wise combinations of the top 
models from one run with the top models of the second run.  Variables were 
extracted from each pair and then combined into one pool, with redundant 
variables, when they existed, thrown out.   If each 5-variable model lacks 
redundant variables, this leaves a pool of ten variables, and selecting 
combinations of six yields 210 combinations.   
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There are 900 pair-wise combinations of 30 with 30, leading to 900 total 
pools. Thus, the total number of models is potentially 900*210 = 189,000.  In 
practice, many duplicate models existed and were eliminated, but the 
elimination of duplicate models was offset by the expansion of sub-interaction 
terms.  Thus, the pool actually involved twelve or more variables.  In our case, 
merging the top thirty models from the PI3K and ErbB families yielded 284,301 
unique additive models without sub-interactions or interactions.   
After completing a run with additive models only, we went one step 
farther by also performing logarithmic expansion (each variable’s logarithmic 
term was also added to the pool), treating sub-interaction terms as a variable 
in their own right, and creating models with interactions and sub-interactions.  
Due to combinatorial explosion, this required a reduction in the number of 
models merged.  We took the top ten models from the PI3K and ErbB families 
and merged them together.  This yielded 880,000 models with interactions and 
sub-interactions, not including the additive models that had already been 
processed.   
Summary	  
In summary, our attempts to find improved prognostic models in invasive 
breast cancer when compared to the clinical gold standards of TNM staging and 
the Nottingham Prognostic Index were not statistically significant.  The 
inability to achieve statistical significance was likely multifactorial.  Broadly, 
our focus on biological markers in the PI3 Kinase pathway only may have been 
insufficient.  There are many biological pathways important in human breast 
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cancer, and their interactions are complex and not fully understood.  Subgroup 
analysis of HER2 positive patients may have increased the significance of our 
results as the importance of the PI3 Kinase pathway is amplified in this group.  
Refinement of our statistical methodology may have further increased 
significance.  Imputing missing data points may have lead to more accurate 
models and narrower confidence intervals.  Use of n-fold or Monte Carlo cross 
validation methods may have also led to narrower confidence intervals.  
Removing patients older than 80 from our cohort may have reduced the 
influence of confounding comorbidities.   Most significantly, we continue to 
believe in the potential of biomarker analysis to improve upon existing 
prognostic models in breast cancer and believe that this is an area deserving of 
continued attention and research efforts.
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R	  Statistical	  Code	  
 
doInit <- function() { 
 
logistic = function(form, dat.sam, samx=samx, res.name, n.fold) { 
 
  options(warn = -1) 
  cv = unique(samx)[order(unique(samx))] 
  n.fold<-length(cv) 
  ret = list() 
  error = numeric(n.fold) 
  failures = 0 
  outcomes = 0 
 
  for( j in cv ) { 
    model.input = data.frame(dat.sam[which(samx!=j),]) 
    names(model.input) = c(names(dat.sam)) 
    #note: line below returns to original data to get the input row 
    outcome.input = data.frame(datx[j,])  
    outcome = NA #in case of failure 
    fxoutput = tryCatch({ 
      model = glm(form, family=binomial, model.input) 
      outcome = predict( model, outcome.input, type="response") 
    }, error = function(ex) { 
        failed = "yes" 
      } ) 
    if(!(is.numeric(fxoutput)) && !(is.na(fxoutput))) {  
      failures = failures + 1 
    } else if(!(is.na(fxoutput))) {  
      outcomes = outcomes + 1  
    } 
    error[j] = as.numeric((outcome > 0.5) != outcome.input$tenyrcens) 
  } 
  ret[[1]] = sum(error[cv], na.rm=T)/sum(!is.na(error[cv])) 
  ret[[2]] = outcomes 
  ret[[3]] = failures 
  return ( ret ) 
} 
 
  assign("logistic", logistic, envir=globalenv()) 
 
  #read in data from data file 
  datx = data.frame(read.table("../YTMA49cleanNPI.txt", sep="\t", 
header=T)) 
  datx$tenyrcens = 1-datx$tenyrcens 
  #specify variables as factors here 
  datx$TumorType = factor(ifelse(datx$TumorType=="IDC-
NOS",0,ifelse(datx$TumorType=="IDC-
lobft",1,ifelse(datx$TumorType=="IDC-
LowRisk",2,ifelse(datx$TumorType=="ILC",3,NA)))))   
  datx$HistoGrade = 
factor(ifelse(datx$HistoGrade==1,"Low",ifelse(datx$HistoGrade==2,"Mediu
m",ifelse(datx$HistoGrade==3,"High",NA)))) 
  datx$NuGrade = factor(datx$NuGrade) 
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  datx$Laterality = factor(ifelse(datx$Laterality == 
"L","L",ifelse(datx$Laterality=="R","R",ifelse(datx$Laterality=="B","Z"
,NA)))) 
  datx$pTumor = factor(datx$pTumor) 
  datx$pMet = factor(datx$pMet) 
  datx$pNode = factor(datx$pNode) 
  datx$PathER = factor(datx$PathER) 
  datx$PathPR = factor(datx$PathPR) 
  datx$PathHER2 = factor(datx$PathHER2) 
  datx$NPI = factor(datx$NPI) 
  assign("datx", datx, envir=globalenv()) 
} 
 
doBootstrap <- function(iter, offset) { 
  res.name <- "tenyrcens" 
  set.seed(as.integer(iter)) #sets seed for random number generator 
  #read in formulas from text file 
  formulas = 
data.frame(read.table(paste("formulas",iter,".txt",sep=""))) 
  #only takes one formula per input file 
  form = as.formula(as.character(formulas[1,1]))    
  n.confidence = 1000 
  misclassifications = numeric(1:n.confidence) 
  successes = numeric(1:n.confidence) 
  failures = numeric(1:n.confidence) 
  for( i in 1:n.confidence ) { 
    #build an array of the row values to sample 
    samx<-sample(c(1:nrow(datx)),nrow(datx),replace=TRUE)  
    #the data transformed by sampling  
    dat.sam <- datx[samx,]  
    #rerun the sampling algorithm if all rows are 0 or 1 
    while( sum(dat.sam[,res.name]) == nrow(dat.sam) | 
sum(dat.sam[,res.name]) == 0 ) {  
      samx = sample(c(1:nrow(datx)), nrow(datx), replace=T) 
      dat.sam = datx[samx,] 
    } 
     
    ret = logistic(form, dat.sam, samx=samx, res.name=res.name, 
n.fold=nrow(dat.sam)) 
    misclassifications[i] = ret[[1]] 
    successes[i] = ret[[2]] 
    failures[i] = ret[[3]] 
  } 
   
  quants = quantile(misclassifications,c(0.025,0.975),na.rm=TRUE) 
  results.names = 
list(c(as.character(formulas[1,1])),c("mean","median",".025",".975","su
ccesses","failures")) 
  results = matrix(nrow=1, ncol=6, dimnames=results.names) 
  results[1,] = 
rbind(mean(misclassifications),median(misclassifications),quants[1],qua
nts[2],mean(successes),mean(failures)) 
  results = round(results,3) 
  #write the results out to a numbered text file 
  write.table(results,file=paste("results",iter,".txt",sep="")) 
} 
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#for running the bootstrap 
doInit() 
doBootstrap(commandArgs()[5], commandArgs()[6]) 
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Tables	  
Table	  One:	  AQUA-­‐Measured	  Variables	  (Hormonal	  Receptors	  and	  PI3	  
Kinase	  pathway)	  
Variable Explanation Variable Explanation 
ER Estrogen Receptor PR Progesterone Receptor 
EGFR Endothelial Growth 
Factor Receptor 
HER2 Human Epidermal 
Growth Factor Receptor 
2 
HER3 Human Epidermal 
Growth Factor Receptor 
3 
HER4 Human Epidermal 
Growth Factor Receptor 
4 
ERK Extracellular signal-
Related Kinases 
PTEN Phosphatase and Tensin 
Homolog 
PI3Kp85 PI3 Kinase Pathway FOX03 PI3 Kinase Pathway 
eIF4E PI3 Kinase Pathway p27kip1 PI3 Kinase Pathway 
BCL2 PI3 Kinase Pathway AKT1 PI3 Kinase Pathway 
AKT2 PI3 Kinase Pathway AKT3 PI3 Kinase Pathway 
CMYC PI3 Kinase Pathway CyclinD1 PI3 Kinase Pathway 
FOX01 PI3 Kinase Pathway MTOR PI3 Kinase Pathway 
NFkB PI3 Kinase Pathway p70S6K PI3 Kinase Pathway 
PI3Kp110 PI3 Kinase Pathway   
Table	  Two:	  Clinical	  Variables	  
Variable Explanation Variable Explanation 
DiagAge Age at Diagnosis pMet Metastasis (TMN) 
pTumor Tumor Size (TMN) pNode Nodal status (TMN) 
HistoGrade Histologic Grade NuGrade Nuclear Grade 
Laterality Light or Right PathER Estrogen Receptor 
(pathologist-scored) 
PathPR Progesterone Receptor 
(pathologist-scored) 
PathHER2 HER2 Receptor 
(pathologist-scored) 
TumorType Histologic Type   
 
Complete	  Univariate	  Results	  	  
Univariate Mis.Est. AUC n Mean 0.025 0.975 
NPI 0.326 0.644 473 0.326 0.292 0.359 
~pNodal Stage 0.353 0.597 539 0.372 0.322 0.493 
43 
TNM 0.367 0.609  0.367 0.313 0.447 
~Metastasis 
Stage 0.368 0.537 536 0.367 0.334 0.398 
~Fox01_NU 0.369 0.524 434 0.375 0.336 0.415 
~AKT1_TM 0.373 0.5 415 0.374 0.335 0.412 
~PI3Kp110_TM 0.377 0.539 403 0.386 0.343 0.431 
~mTOR_TM 0.382 0.5 429 0.383 0.346 0.419 
~NFkB_TM 0.383 0.5 439 0.389 0.35 0.433 
~HER2_MB 0.385 0.524 535 0.391 0.357 0.425 
~PR_NU 0.385 0.5 473 0.385 0.352 0.421 
~PTEN_TM 0.386 0.5 446 0.387 0.353 0.434 
~p70S6K_NU 0.387 0.506 439 0.389 0.353 0.428 
~CyclinD1_TM 0.388 0.5 456 0.389 0.356 0.424 
~Nuclear Grade 0.39 0.569 502 0.400 0.358 0.538 
~cmyc_TM 0.39 0.506 323 0.393 0.346 0.443 
~Tumor Stage 0.392 0.566 502 0.373 0.332 0.506 
~p70S6K_TM 
(repeat) 0.392 0.506 439 0.388 0.351 0.423 
~AKT2_TM 0.392 0.5 449 0.395 0.359 0.433 
~eIF4E_NN 0.394 0.505 480 0.402 0.364 0.442 
~BCL2_TM 0.394 0.5 462 0.396 0.359 0.449 
~Age at 
Diagnosis 0.395 0.5 539 0.399 0.366 0.441 
~PI3Kp85_NU 0.397 0.498 466 0.399 0.365 0.436 
~Laterality 0.398 0.5 530 0.407 0.367 0.47 
~p27kip1_NU 0.398 0.5 427 0.402 0.363 0.439 
44 
~ER_NU 0.4 0.5 515 0.423 0.369 0.444 
~AKT3_NU 0.401 0.5 362 0.403 0.361 0.446 
~FOXO3A_MB 0.401 0.498 401 0.401 0.363 0.442 
~PI3Kp85_NN 
(repeat) 0.401 0.495 466 0.400 0.365 0.435 
~AKT3_MB 
(repeat) 0.403 0.508 362 0.404 0.363 0.449 
~p27kip1_MB  0.403 0.5 427 0.404 0.365 0.447 
~HER3_NN 0.404 0.511 488 0.402 0.365 0.439 
~EGFR_MB 0.405 0.506 514 0.395 0.359 0.432 
~PathER 0.407 0.5 509 0.424 0.372 0.642 
~HER4_NN 0.409 0.5 472 0.409 0.373 0.446 
~PathPR 0.409 0.5 494 0.433 0.377 0.664 
~AKT3_NN 
(repeat) 0.412 0.497 362 0.403 0.362 0.444 
~ERK_TM 0.413 0.5 404 0.417 0.377 0.466 
~TumorType 0.423 0.515 539 0.406 0.365 0.462 
~Histologic 
Grade 0.460 0.510 265 0.500 0.414 0.766 
~PathHER2 0.471 0.5 499 0.423 0.379 0.492 
Selected	  Multivariate	  Results	  
5-variate Mis. Est. AUC n Mean 0.025 0.975 
Fox01_NU + AKT1_NU + 
mTOR_MB + p70S6K_NU 
+ AVG_BCL2_TM + 
Fox01_NU*AKT1_NU*mT
OR_MB 
0.295 0.587 285 0.33 0.274 0.393 
Fox01_NU + AKT1_NU + 
mTOR_MB + 
AVG_BCL2_TM + 
0.302 0.574 285 0.33 0.277 0.391 
45 
p70S6K_NN + 
Fox01_NU*mTOR_MB*p7
0S6K_NN 
Fox01_NU + 
PI3Kp110_TM + 
mTOR_MB + p70S6K_NN 
+ FOXO3A_NN + 
Fox01_NU*PI3Kp110_TM
*mTOR_MB*FOXO3A_N
N 
0.301 0.666 279 0.337 0.28 0.401 
ER_NU + HER3_NN + 
HER4_NN + pMet + 
pTumor + 
HER3_NN*pTumor 
0.310 0.663 393 0.345 0.294 0.399 
ER_NU + HER3_NN + 
HER4_TM + pMet + 
pTumor + 
HER3_NN*pTumor 
0.315 0.659 394 0.348 0.295 0.406 
HER3_NN + 
log(HER4_NU/HER4_NN) 
+ PathPR + PathHER2 + 
pTumor + 
log(HER4_NU/HER4_NN)
*PathPR*PathHER2 
0.316 0.702 380 0.355 0.301 0.411 
log(HER4_NU/HER4_NN) 
+ PathER + PathPR + 
pMet + pNode + 
PathER*PathPR*pNode 
0.317 0.699 441 0.373 0.314 0.443 
 
 
6-variate Mis. 
Est. AUC n Mean 0.025 0.975 
Fox01_NU + AKT1_NU 
+ mTOR_MB + 
AKT2_NN + 
AVG_BCL2_TM + 
p70S6K_NN + 
Fox01_NU*AKT1_NU*m
TOR_MB 
0.295 0.593 285 0.331 0.273 0.401 
Fox01_NU + AKT1_NU 
+ mTOR_MB + 
cmyc_NU + 
AVG_BCL2_TM + 
p70S6K_NN + 
AKT1_NU*p70S6K_NN 
0.297 0.627 195 0.333 0.266 0.403 
Fox01_NU + AKT1_NN 0.295 0.590 285 0.334 0.277 0.403 
46 
+ mTOR_MB + 
p70S6K_NU + 
AKT2_NN + 
AVG_BCL2_TM + 
Fox01_NU*mTOR_MB*p
70S6K_NU 
ER_NU + HER3_NN + 
HER4_NN + 
log(HER4_NU/HER4_N
N) + pMet + pTumor + 
HER3_NN*pTumor 
0.313 0.663 393 0.348 0.298 0.41 
ER_NU + HER2_MB + 
HER3_NN + HER4_MB 
+ HER4_NN + pTumor + 
HER3_NN*pTumor 
0.311 0.658 395 0.348 0.3 0.402 
 
 
47 
 
6-variate “Merge” Mis. 
Est. AUC n Mean 0.025 0.975 
AVG_BCL2_TM + 
Fox01_NU*AKT1_NU*m
TOR_MB + HER4_MB + 
HER4_NN + 
p70S6K_NU + pTumor + 
HER4_NN*pTumor 
0.247 0.728 243 0.303 0.240 0.370 
AKT1_NU + 
AVG_BCL2_TM + 
Fox01_NU*mTOR_MB*p
70S6K_NN + HER4_MB 
+ HER4_NN + pTumor + 
HER4_MB*pTumor 
0.259 0.704 243 0.304 0.243 0.379 
AKT1_NU + 
AVG_BCL2_TM + 
Fox01_NU*mTOR_MB*p
70S6K_NN + HER4_MB 
+ HER4_NN + pTumor + 
HER4_NN*pTumor 
0.259 0.713 243 0.304 0.238 0.371 
AVG_BCL2_TM + 
Fox01_NU*AKT1_NU*m
TOR_MB + HER4_MB + 
HER4_NN + 
p70S6K_NN + pTumor + 
HER4_NN*pTumor 
0.247 0.728 243 0.305 0.241 0.374 
AVG_BCL2_TM + 
Fox01_NU*AKT1_NU*m
TOR_MB + HER4_MB + 
HER4_NN + 
p70S6K_NN + pTumor + 
HER4_MB*pTumor 
0.259 0.731 243 0.305 0.240 0.378 
Fox01_NU + 
Fox01_NU*AKT1_NU*m
TOR_MB + 
HER3_NN*pTumor + 
HER4_NN + 
p70S6K_NU + pMet + 
Fox01_NU*HER3_NN*p
Tumor 
0.258 0.690 260 0.325 0.263 0.394 
 
 
 
